NovAccess Global Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XSNX Over the counter 8731 https://novaccessglobal.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NovAccess Global Inc

NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies - Jun 1st, 2023 12:40 pm
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements - May 11th, 2023 1:00 pm
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award - Mar 15th, 2023 1:00 pm
NovAccess Global to Present at World Orphan Drug Congress - Feb 16th, 2023 2:00 pm
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress - Feb 3rd, 2023 2:00 pm
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division - Jan 5th, 2023 5:15 pm
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate - Nov 22nd, 2022 1:00 pm
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board - Nov 10th, 2022 7:00 pm
NovAccess Global Announces Virtual Annual Shareholders' Meeting - Nov 8th, 2022 2:00 pm
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 - Oct 26th, 2022 11:00 am
NovAccess Global Announces Fireside Chat with Board Member Perspectives - Oct 20th, 2022 1:17 pm
NovAccess Global Announces Fireside Chat Series for the Investment Community - Sep 29th, 2022 8:00 pm
NovAccess Global Announces Effectiveness of Form S-1 Registration Statement - Sep 22nd, 2022 1:00 pm
NovAccess Global Announces Uplisting to OTCQB - Aug 10th, 2022 1:00 pm
CORRECTION: NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1 - Jul 19th, 2022 4:15 pm
NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1 - Jul 19th, 2022 1:00 pm
NovAccess Global CEO Dwain Irvin Featured on MoneyTV - Jun 14th, 2022 6:05 pm
This Week on MoneyTV with Donald Baillargeon, 6/10 - Jun 10th, 2022 9:00 am